Fate Therapeutics, Inc. (FATE)
- Previous Close
1.0100 - Open
1.0000 - Bid 1.0200 x 200
- Ask 1.1000 x 200
- Day's Range
1.0000 - 1.1200 - 52 Week Range
0.6600 - 5.9200 - Volume
2,096,502 - Avg. Volume
2,437,072 - Market Cap (intraday)
122.657M - Beta (5Y Monthly) 2.33
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4900 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.69
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
www.fatetherapeutics.comRecent News: FATE
View MorePerformance Overview: FATE
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FATE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FATE
View MoreValuation Measures
Market Cap
115.78M
Enterprise Value
-41.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.94
Price/Book (mrq)
0.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.97%
Return on Equity (ttm)
-49.23%
Revenue (ttm)
13.34M
Net Income Avi to Common (ttm)
-175.88M
Diluted EPS (ttm)
-1.4900
Balance Sheet and Cash Flow
Total Cash (mrq)
240.42M
Total Debt/Equity (mrq)
28.89%
Levered Free Cash Flow (ttm)
-76.88M